Mylan disclosed it is part of the Justice Department’s probe into opioid marketing despite its minimal footprint in the opioid business.
In its quarterly securities filing, the company said it received a DOJ subpoena for information “relating to opioids manufactured, marketed or sold by” the company between early 2013 and the end of 2016.
Mylan produces only 1 percent of opioid painkillers nationwide, but this is the second time it has found itself included in federal efforts to address the addiction crisis. In March, Sen. Claire McCaskill (D-Mo.) sent several letters to opioid manufacturers requesting internal estimates on potential for abuse and addiction as well as marketing plans and compliance reports. Mylan was among the recipients, along with Purdue Pharma, Johnson & Johnson, and Depomed.
Mallinckrodt also received a subpoena in late July from the DOJ. Like Mylan, Mallinckrodt has also come under scrutiny from McCaskill, who in May sent the company a request for more information on price increases for its injectable opioid alternative Ofirmev.